VALUMEDIUM SIGNALFINANCIAL10-K

Value Line experienced a meaningful decline in operating income while maintaining positive operating cash flow growth and strengthening its balance sheet position.

The substantial decrease in operating income signals potential margin pressure or revenue challenges that warrant close monitoring, though this is partially offset by improved cash generation. The company continues returning capital to shareholders through buybacks while building current assets, suggesting management remains confident in the underlying business fundamentals despite near-term profitability headwinds.

Comparing 2025-07-29 vs 2024-07-26View on EDGAR →
FINANCIAL ANALYSIS

Value Line's financial performance presents a mixed picture with operating income declining meaningfully to $6.0M while operating cash flow grew modestly to $20.2M, indicating potential timing differences or non-cash charges affecting profitability. Current assets strengthened to $79.9M, and the company maintained its capital return program with $453K in share repurchases. The divergence between operating income and cash flow generation suggests investors should examine the underlying drivers of this disconnect in the detailed filings.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-34.5%
$9.1M→$6.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Share Buybacks
Cash Flow
-13.4%
$523K→$453K

Buyback activity reduced 13.4% — capital being redeployed elsewhere or cash conservation underway.

Operating Cash Flow
Cash Flow
+12.9%
$17.9M→$20.2M

Operating cash flow grew 12.9% — strong conversion of earnings to cash, healthy business fundamentals.

Current Assets
Balance Sheet
+12.5%
$71.0M→$79.9M

Current assets grew 12.5% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2025-07-29
PRIOR — 2024-07-26
ADDED
There were 9,409,522 shares of the registrant s Common Stock outstanding at June 30, 2025.
Other unknown or unpredictable factors which may involve external factors over which we may have no control could also have material adverse effects on future results.
Likewise, changes we make in our plans, objectives, strategies, or intentions, which may occur at any time in our discretion, could also have material favorable or adverse effects on our future results.
is the controlling shareholder of the Company and, as of April 30, 2025, owns 91.74% of the outstanding shares of the common stock of the Company.
Value Line Select ETFs recommends a new ETF for purchase each month.
+7 more — sign up free →
REMOVED
valu20240430_10k.htm 0000717720 VALUE LINE INC false --04-30 FY 2024 false false false false 4,136 7,240 31 36 0.10 0.10 30,000,000 30,000,000 10,000,000 10,000,000 577,517 565,460 39,928 0 55,805,000 5,820,000 0 0 http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet 3.72 http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet 1,499,000 1,499,000 1 Reported within Long-Term Assets on the Consolidated Condensed Balance Sheets.
At July 31, 2023 and April 30, 2023, EAM's total liabilities included a payable to VLI for its accrued non-voting revenues interest and non-voting profits interest of $2,833,000 and $2,601,000, respectively.
Were acquired during the $2 million repurchase program authorized in July 2021 and the $2 million repurchase program authorized in March 2022.
Were acquired during the $3 million repurchase program authorized in May 2022 and the $3 million repurchase program authorized in October 2022.
Represents EAM's net income, after giving effect to Value Line s non-voting revenues interest, but before distributions to voting profits interest holders and to the Company in respect of its 50% non-voting profits interest.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →